Most Viewed Articles - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Most Viewed Articles

Correlating Product Lifecycle and Manufacturing Site Characteristics with Critical-to-Quality Product Deviations

September 2, 2012

Pharmaceutical Technology

MIT survey results address product and site characteristics that statistically correlate with quality performance.

Strategies for High Containment

September 1, 2012

Pharmaceutical Technology Europe

Experts share insight on facility design and operations for high-potency manufacturing.

Janssen Pharmaceuticals to Pay $181 Million in Multistate Consumer-Protection Suit

August 31, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

The Johnson & Johnson subsidiary Janssen Pharmaceuticals has announced a settlement and consent decree with 36 states and the District of Columbia in regards to previously disclosed allegations related to the company's marketing and promotional practices relating to Risperdal (risperidone).

Pfizer and Mylan Partner to Develop Generic Drugs in Japan

August 27, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

Pfizer and Mylan have agreed to establish an exclusive long-term collaboration to develop, manufacture, distribute, and market generic drugs in Japan. The products included in the collaboration are expected to be sold under the Pfizer brand with joint labeling.

EMA Deals with Manufacturing Deficiencies for Cancer Medicine

August 27, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

The European Medicines Agency has recommended that the anticancer medicine DepoCyte be recalled from EU countries following the discovery of manufacturing deficiencies at Pacira Pharmaceuticals' San Diego site.

Eli Lilly Receives $1.3 Billion Following Bristol-Myers Squibb's Acquisition of Amylin Pharmaceuticals

August 22, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

Eli Lilly has received $1.3 billion for payment of financial obligations from Amylin Pharmaceuticals following Bristol-Myers Squibb's acquisition of Amylin Pharmaceuticals earlier this month.

Myriad Genetics Receives Favorable Ruling on Gene Patentability

August 22, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

Myriad Genetics reported that a US federal appeals court has ruled that the company's composition of matter claims covering isolated DNA of the BRCA 1 and BRCA 2 genes are patent-eligible material under federal patent law. The court, however, denied the company's effort to patent methods of "comparing" or "analyzing" DNA sequences.

Grey-Market Distributor Convicted of Defrauding FDA

August 20, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

South Carolina-based Altec Medical pleaded guilty to one count of conspiring to defraud FDA and to commit federal offenses in connection with a drug-diversion scheme that lasted from 2007 to 2009.

AstraZeneca and Bristol-Myers Squibb Extend Diabetes Alliance

August 13, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

AstraZeneca has paid approximately $3.2 billion to extend its diabetes alliance with Bristol-Myers Squibb (BMS), following BMS's recently completed acquisition of Amylin Pharmaceuticals.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
Click here